Citations

Showing 10 of 108162 citations.

ROBO1 Promotes Homing, Dissemination, and Survival of Multiple Myeloma within the Bone Marrow Microenvironment
Bianchi, Giada , Czarnecki, Peter G. , Ho, Matthew , Roccaro, Aldo M. , Sacco, Antonio , Kawano, Yawara , Gullà, Annamaria , Samur, Anıl Aktaş , Chen, Tianzeng , Wen, Kenneth , Moscvin, Maria , Wu, Xinchen, Camci‐Unal, Gulden , Vià, Matteo Da , Bolli, Niccolò , Sewastianik, Tomasz , Carrasco, Ruben D. , Ghobrial, Irene M. , Tai, Yu‐Tzu , Da Vià, Matteo C , Bolli, Niccolo' , Sewastianik, Tomasz , Roccaro, Aldo M , Bianchi, Giada , Ghobrial, Irene M , Gulla, Annamaria , Ho, Matthew , Anderson, Kenneth C.

Mayo Clinic

Blood Cancer Discovery | April 10, 2021 | Volume: 2 | Issue: 4 | Pages: 338-353

10.1158/2643-3230.bcd-20-0164 | PMID 34268498 Get It

Abstract The bone marrow (BM) microenvironment actively promotes multiple myeloma pathogenesis, and therapies targeting both cancer cells and the niche are highly effective. We were interested in identifying novel signaling pathways supporting multiple myeloma–BM cross-talk. Mutations in the transmembrane receptor Roundabout 1 (ROBO1) were recently identified in patients with multiple myeloma; however, their functional consequences are uncertain. Through protein structure–function studies, we discovered that ROBO1 is necessary for multiple myeloma adhesion to BM stromal and endothelial cells and that ROBO1 knockout (KO) compromises BM homing and engraftment in a disseminated mouse model. ROBO1 KO significantly decreases multiple myeloma proliferation in vitro and intra- and extramedullary tumor growth in vivo. Mechanistically, the ROBO1 C-terminus is cleaved in a ligand-independent fashion and is sufficient to promote multiple myeloma proliferation. Vice versa, mutants lacking the cytoplasmic domain, including the human-derived G674* truncation, act dominantly negative. Interactomic and RNA-sequencing studies suggest that ROBO1 may be involved in RNA processing, supporting further studies. Significance: ROBO1 is highly expressed in t(4;14) multiple myeloma and supports homing and dissemination to the BM niche. ROBO1 knockout causes reduced tumor growth in intramedullary and extramedullary myeloma animal models, while the ROBO1 C-terminus is cleaved in multiple fragments and it is necessary and sufficient to sustain myeloma proliferation.
Post-marketing reports of pancreatitis in eluxadoline-treated patients pre and post US label change
Cash, Brooks D. , Lacy, Brian E. , Watton, Cheryl, Schoenfeld, Philip , Weissman, Darren

Mayo Clinic

Therapeutic Advances in Gastroenterology | April 10, 2021 | Volume: 14 | Issue: No issue available | Pages: No page available

10.1177/17562848211001725 | PMID 33953798 Get It

Background: Eluxadoline, a United States Food and Drug Administration (FDA)-approved treatment for irritable bowel syndrome with diarrhea (IBS-D), underwent a change to its US prescribing information on 21 April 2017, contraindicating it in patients without a gallbladder due to increased risk of pancreatitis. This study aimed to elucidate the potential role of eluxadoline’s label change on the number of reported spontaneous adverse events (AEs) of pancreatitis. Methods: A pharmacovigilance database (Oracle Argus) was searched for eluxadoline use and spontaneously reported pancreatitis cases from 1 January 2016 to 30 June 2018. Pancreatitis cases were reported as a proportion of the total number of reported AE cases in the safety database. The FDA’s adverse event reporting system (AERS) was also interrogated for cases of pancreatitis concomitantly reported with eluxadoline use. Results: In patients who received eluxadoline, 273 reported cases of pancreatitis were recorded (total AEs n = 2191; 12.5%). When known, 28.2% of patients reporting pancreatitis had intact gallbladders (49/174). Eluxadoline was withdrawn in 97.5% of cases, with 87.1% of patients improving or recovered at time of reporting. Importantly, the reporting proportion of pancreatitis cases decreased from 14.4% to 8.9% post label change. Findings were supported by the AERS results, which demonstrated a decrease in reporting proportion from 21.2% to 12.8%. Conclusions: While cautious interpretation is warranted, post-marketing data indicate that the contraindication of eluxadoline in patients without a gallbladder led to reduced reported cases of pancreatitis, with no additional reports of moderately severe or severe cases. Eluxadoline is a safe and well-tolerated treatment option for IBS-D when used according to the label.
White matter abnormalities are key components of cerebrovascular disease impacting cognitive decline
Vemuri, Prashanthi , Graff‐Radford, Jonathan , Lesnick, Timothy G. , Przybelski, Scott A. , Reddy, Ashritha L, Lowe, Val J. , Mielke, Michelle M. , Petersen, Ronald C. , Jack, Clifford R. , Mielke, Michelle M , Jack, Clifford R , Vemuri, Prashanthi , Reid, Robert I. , Reddy, Ashritha L, Machulda, Mary M. , Knopman, David S.

Mayo Clinic

Brain Communications | April 10, 2021 | Volume: 3 | Issue: 2 | Pages: No page available

10.1093/braincomms/fcab076 | PMID 33937772 Get It

Abstract While cerebrovascular disease can be observed in vivo using MRI, the multiplicity and heterogeneity in the mechanisms of cerebrovascular damage impede accounting for these measures in ageing and dementia studies. Our primary goal was to investigate the key sources of variability across MRI markers of cerebrovascular disease and evaluate their impact in comparison to amyloidosis on cognitive decline in a population-based sample. Our secondary goal was to evaluate the prognostic utility of a cerebrovascular summary measure from all markers. We included both visible lesions seen on MRI (white matter hyperintensities, cortical and subcortical infarctions, lobar and deep microbleeds) and early white matter damage due to systemic vascular health using diffusion changes in the genu of the corpus callosum. We identified 1089 individuals aged ≥60 years with concurrent amyloid-PET and MRI scans from the population-based Mayo Clinic Study of Aging. We divided these into discovery and validation datasets. Using the discovery dataset, we conducted principal component analyses and ascertained the main sources of variability in cerebrovascular disease markers. Using linear regression and mixed effect models, we evaluated the utility of these principal components and combinations of these components for the prediction of cognitive performance along with amyloidosis. Our main findings were (i) there were three primary sources of variability among the CVD measures—white matter changes are driven by white matter hyperintensities and diffusion changes; number of microbleeds (lobar and deep); and number of infarctions (cortical and subcortical); (ii) Components of white matter changes and microbleeds but not infarctions significantly predicted cognition trajectories in all domains with greater contributions from white matter; and (iii) The summary vascular score explained 3–5% of variability in baseline global cognition in comparison to 3–6% variability explained by amyloidosis. Across all cognitive domains, the vascular summary score had the least impact on memory performance (∼1%). Though there is mechanistic heterogeneity in the cerebrovascular disease markers measured on MRI, these changes can be grouped into three components and together explain variability in cognitive performance equivalent to the impact of amyloidosis on cognition. White matter changes represent dynamic ongoing damage, predicts future cognitive decline across all domains and diffusion measurements help capture white matter damage due to systemic vascular changes. Therefore, measuring and accounting for white matter changes using diffusion MRI and white matter hyperintensities along with microbleeds will allow us to capture vascular contributions to cognitive impairment and dementia.
Vendor‐provided clinical physics services are a disservice to patients and the medical physics profession
Halvorsen, Per H. , Rong, Yi , Rong, Yi , Wang, Dongxu

Mayo Clinic

Journal of Applied Clinical Medical Physics | April 10, 2021 | Volume: 22 | Issue: 4 | Pages: 4-7

10.1002/acm2.13243 | PMID 33837654 Get It

Do histone deacytelase inhibitors and azacitidine combination hold potential as an effective treatment for high/very-high risk myelodysplastic syndromes?
Badar, Talha , Badar, Talha , Atallah, Ehab

Mayo Clinic

Expert Opinion on Investigational Drugs | April 10, 2021 | Volume: 30 | Issue: 6 | Pages: 665-673

10.1080/13543784.2021.1915986 | PMID 33836635 Get It

Response to Letter to the Editor From Idrees and Bianco: “Treatment of Thyroid Dysfunction and Serum Lipids: A Systematic Review and Meta-Analysis”
Kotwal, Anupam , Murad, M. Hassan , Alahdab, Fares , Murad, M Hassan , Kudva, Yogish C , Alahdab, Fares

Mayo Clinic

The Journal of Clinical Endocrinology & Metabolism | April 10, 2021 | Volume: 106 | Issue: 9 | Pages: e3792-e3793

10.1210/clinem/dgab228 | PMID 33837395 Get It

Epidemiology of Cardiogenic Shock and Cardiac Arrest Complicating Non-ST-Segment Elevation Myocardial Infarction: 18-Year US Study
Vallabhajosyula, Saraschandra , Prasad, Abhiram , Sangaralingham, Lindsey R. , Shah, Nilay D. , Dunlay, Shannon M. , Vallabhajosyula, Saraschandra , Prasad, Abhiram , Jentzer, Jacob C. , Kashani, Kianoush

Mayo Clinic

ESC Heart Failure | April 10, 2021 | Volume: 8 | Issue: 3 | Pages: 2259-2269

10.1002/ehf2.13321 | PMID 33837667 Get It

Abstract Aims This study aims to evaluate the impact of the combination of cardiogenic shock (CS) and cardiac arrest (CA) complicating non-ST-segment elevation myocardial infarction (NSTEMI). Methods and results Adult (>18 years) NSTEMI admissions using the National Inpatient Sample database (2000 to 2017) were stratified by the presence of CA and/or CS. Outcomes of interest included in-hospital mortality, early coronary angiography, hospitalization costs, and length of stay. Of the 7 302 447 hospitalizations due to NSTEMI, 147 795 (2.0%) had CS only, 155 522 (2.1%) had CA only, and 41 360 (0.6%) had both CS and CA. Compared with 2000, the adjusted odds ratios (ORs) and 95% confidence interval (CIs) for CS, CA, and both CS and CA in 2017 were 3.75 (3.58–3.92), 1.46 (1.42–1.50), and 4.52 (4.16–4.87), respectively (all P < 0.001). The CS + CA (61.2%) cohort had higher multiorgan failure than CS (42.3%) and CA only (32.0%) cohorts, P < 0.001. The CA only cohort had lower rates of overall (52% vs. 59–60%) and early (17% vs. 18–27%) angiography compared with the other groups (all P < 0.001). CS + CA admissions had higher in-hospital mortality compared with those with CS alone (aOR 4.12 [95% CI 4.00–4.24]), CA alone (aOR 1.69 [95% CI 1.65–1.74]), or without CS/CA (aOR 22.66 [95% CI 22.06–23.27]). The presence of CS, either alone or with CA, was associated with higher hospitalization costs and longer hospital length of stay. Conclusions The combination of CS and CA is associated with higher rates of acute non-cardiac organ failure and in-hospital mortality in NSTEMI admissions as compared with those with either CS or CA alone.
Osteopathic manipulative medicine in the management of headaches associated with postconcussion syndrome
Esterov, Dmitry , Thomas, Alphonsa, Weiss, Kyle

Mayo Clinic

Journal of Osteopathic Medicine | April 10, 2021 | Volume: 121 | Issue: 7 | Pages: 651-656

10.1515/jom-2020-0035 | PMID 33831981 Get It

Abstract Context Previous studies have demonstrated the effectiveness of osteopathic manipulative treatment (OMT) for various headache types, with limited evidence of its use for headaches related to mild traumatic brain injury (MTBI). No studies prior studies were found regarding OMT for headaches in patients with postconcussion syndrome (PCS), defined as symptom persistence for longer than 3 months after MTBI. Objectives To evaluate OMT for headaches in patients with PCS. Methods A controlled pilot study was conducted of patients with PCS who presented to an outpatient interdisciplinary rehabilitation clinic; patients with symptoms lasting longer than 3 months were enrolled and randomly assigned to an OMT treatment group or a control group. Primary outcome measures were immediate change in headache scores according to a Visual Analog Scale (VAS) and change in the six item Headache Impact Test (HIT-6) between baseline and follow up visits. The participants in the control group completed the HIT-6 between baseline and follow up visits but did not receive OMT and did not complete the VAS. Mean immediate VAS score change for the treatment group and mean improvement in HIT-6 scores for both groups between baseline and follow up were analyzed for statistical significance. Results A total of 26 patients were included in this study: 13 (50%) in the treatment group and 13 (50%) in the control group. Six patients (23.1%), three from each group, did not complete the study, so 10 subjects in each group were included in the final analysis. Statistically significant improvement in VAS scores was seen immediately after OMT in the treatment group (mean change, 2.1;p=0.002). Mean HIT-6 scores showed improvement in the treatment group compared with the control group, although the change was not statistically significant (p=0.15) from baseline to follow up visit. No adverse effects from treatments were noted. Conclusions Patients with headaches secondary to PCS showed immediate benefit in headache pain intensity after OMT. However, no sustained benefit was found on the follow up visit compared with the control group.
An 11-year Institutional Review of Nipple-Areolar Complex Tattooing for Breast Reconstruction
Weissler, Jason M., Curiel, Daniel , Alsayed, Ahmed , Dudakovic, Amela, Harless, Christin A., Nguyen, Minh-Doan T. , Kuruoglu, Doga

Mayo Clinic

Annals of Plastic Surgery | April 9, 2021 | Volume: 87 | Issue: 5 | Pages: e86-e91

10.1097/sap.0000000000002820 | PMID 33833170 Get It

Background Nipple-areolar complex (NAC) tattooing remains a simple and safe procedure, which complements breast reconstruction. This study reviews 11 years of NAC tattooing to identify risk factors for tattoo-related complications. Methods Patients undergoing NAC tattooing from January 2009 to March 2020 were reviewed. Patient information, reconstructive, and tattoo procedural details were analyzed. Tattoo-related breast infections, defined as breast redness requiring antibiotic therapy within 30 days after tattoo, were captured. Patients with reactive breast redness during the first 2 postprocedural days were excluded. Results Overall, 539 patients (949 breasts) were included. Implant-based reconstruction (IBR) was performed in 73.6% of breasts (n = 698), whereas 26.4% (n = 251) underwent autologous-based reconstruction (ABR). Acellular-dermal matrix was used in 547 breasts (57.6%). There as a 13.7% (n = 130) of breasts that underwent pretattoo radiation. There was a 65.3% (n = 456) of breasts that underwent subpectoral IBR, whereas 34.7% (n = 242) breasts underwent prepectoral IBR. Tattoo-related infection rate was 2.2% (n = 21 breasts). Mean time to infection was 6.5 ± 5.3 days. There was a 85.7% (n = 18) of infections that occurred in IBR patients, one third occurring in radiated patients. There was a 95.2% (n = 20) of infections that were treated with oral antibiotics only. One explantation was performed after failed intravenous antibiotics. On multivariable analysis, radiation history (odds ratio, 4.1, P = 0.007) and prepectoral IBR (odds ratio, 2.8, P = 0.036) were independent predictors of tattoo-related infection. Among irradiated breasts, breasts with IBR had greater odds of developing tattoo-related infection versus breasts with ABR (P = 0.025). Conclusions Although tattoo-related infections were uncommon, previous radiation and prepectoral IBR were both found to be independent predictors of tattoo-related breast infection. There is a role for preprocedural prophylactic antibiotics in these patients to mitigate infectious risk.
The Importance of Conceptualizing and Defining Episodes of Lucidity
Block, Laura , Benson, Clark , Griffin, Joan M. , Gilmore‐Bykovskyi, Andrea L

Mayo Clinic

Journal of Gerontological Nursing | April 9, 2021 | Volume: 47 | Issue: 4 | Pages: 5-5

10.3928/00989134-20210326-01 | PMID 34038253 Get It